162 related articles for article (PubMed ID: 30147316)
1. Evaluation of the antibacterial activity of tilmicosin-SLN against
Zhu L; Cao X; Xu Q; Su J; Li X; Zhou W
Int J Nanomedicine; 2018; 13():4747-4755. PubMed ID: 30147316
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo.
Wang XF; Zhang SL; Zhu LY; Xie SY; Dong Z; Wang Y; Zhou WZ
Vet J; 2012 Jan; 191(1):115-20. PubMed ID: 21900026
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization, and pharmacokinetics of tilmicosin- and florfenicol-loaded hydrogenated castor oil-solid lipid nanoparticles.
Ling Z; Yonghong L; Changqing S; Junfeng L; Li Z; Chunyu J; Xianqiang L
J Vet Pharmacol Ther; 2017 Jun; 40(3):293-303. PubMed ID: 27687707
[TBL] [Abstract][Full Text] [Related]
4. Tilmicosin- and florfenicol-loaded hydrogenated castor oil-solid lipid nanoparticles to pigs: Combined antibacterial activities and pharmacokinetics.
Ling Z; Yonghong L; Junfeng L; Li Z; Xianqiang L
J Vet Pharmacol Ther; 2018 Apr; 41(2):307-313. PubMed ID: 29139136
[TBL] [Abstract][Full Text] [Related]
5. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies.
Han C; Qi CM; Zhao BK; Cao J; Xie SY; Wang SL; Zhou WZ
J Vet Pharmacol Ther; 2009 Apr; 32(2):116-23. PubMed ID: 19290940
[TBL] [Abstract][Full Text] [Related]
6. Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Xie S; Wang F; Wang Y; Zhu L; Dong Z; Wang X; Li X; Zhou W
Part Fibre Toxicol; 2011 Nov; 8():33. PubMed ID: 22098626
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Treatment Effects of Tilmicosin Against
Zhou K; Wang X; Chen D; Yuan Y; Wang S; Li C; Yan Y; Liu Q; Shao L; Huang L; Yuan Z; Xie S
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31614726
[TBL] [Abstract][Full Text] [Related]
8. Tilmicosin antibacterial activity and pharmacokinetics in cows.
Ziv G; Shem-Tov M; Glickman A; Winkler M; Saran A
J Vet Pharmacol Ther; 1995 Oct; 18(5):340-5. PubMed ID: 8587151
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off.
Nickerson SC; Owens WE; Fox LK; Scheifinger CC; Shryock TR; Spike TE
J Dairy Sci; 1999 Apr; 82(4):696-703. PubMed ID: 10212455
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antibacterial activity of tilmicosin against
Luo W; Liu J; Zhang S; Song W; Algharib SA; Chen W
J Vet Sci; 2022 Jan; 23(1):e1. PubMed ID: 34931502
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation.
Owens WE; Nickerson SC; Ray CH
J Dairy Sci; 1999 Mar; 82(3):645-7. PubMed ID: 10194686
[TBL] [Abstract][Full Text] [Related]
12. Elimination kinetics of tilmicosin following intramammary administration in lactating dairy cattle.
Smith GW; Davis JL; Baynes RE; Yeatts JL; Barlow BM; Riviere JE
J Am Vet Med Assoc; 2009 Jan; 234(2):245-8. PubMed ID: 19210246
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
[TBL] [Abstract][Full Text] [Related]
14. The controlled release of tilmicosin from silica nanoparticles.
Song M; Li Y; Fai C; Cui S; Cui B
Drug Dev Ind Pharm; 2011 Jun; 37(6):714-8. PubMed ID: 21204738
[TBL] [Abstract][Full Text] [Related]
15. Impact of intramammary tilmicosin infusion as a dry cow therapy.
Mohammadsadegh M
J Vet Pharmacol Ther; 2018 Feb; 41(1):22-27. PubMed ID: 28600854
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.
Xie S; Zhu L; Dong Z; Wang Y; Wang X; Zhou W
Int J Nanomedicine; 2011; 6():547-55. PubMed ID: 21468357
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids.
Xie S; Zhu L; Dong Z; Wang X; Wang Y; Li X; Zhou W
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):382-7. PubMed ID: 21215599
[TBL] [Abstract][Full Text] [Related]
18. Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics.
Xiong J; Zhu Q; Zhao Y; Yang S; Cao J; Qiu Y
J Vet Pharmacol Ther; 2019 May; 42(3):336-345. PubMed ID: 30801755
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes.
Chen X; Wang T; Lu M; Zhu L; Wang Y; Zhou W
Int J Nanomedicine; 2014; 9():2655-64. PubMed ID: 24920902
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intramammary tilmicosin and risk factors for cure of Staphylococcus aureus infection in the dry period.
Dingwell RT; Leslie KE; Duffield TF; Schukken YH; DesCoteaux L; Keefe GP; Kelton DF; Lissemore KD; Shewfelt W; Dick P; Bagg R
J Dairy Sci; 2003 Jan; 86(1):159-68. PubMed ID: 12613861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
